Xencor, Inc Cash and Restricted Cash
Xencor, Inc (XNCR) had Cash and Restricted Cash of $44.85 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $44.85M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.36M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $54.36M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $28.58M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $44.85M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $14.36M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $54.36M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $28.58M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $44.73M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $39.96M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $41.26M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $29.42M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $31.15M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $31.42M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $54.17M 10-K · filed 2026-02-25 |
| 2023-09-30 | $53.11M 10-Q/A · filed 2025-02-24 |
| 2023-06-30 | $34.71M 10-Q/A · filed 2025-02-24 |
| 2023-03-31 | $72.39M 10-Q/A · filed 2025-02-24 |
| 2022-12-31 | $53.94M 10-K · filed 2026-02-25 |
| 2022-09-30 | $52.65M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $49.41M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $78.27M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $143.48M 10-K · filed 2025-02-27 |
| 2021-09-30 | $41.20M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $115.84M 10-Q · filed 2022-08-03 |
| 2021-03-31 | $176.97M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $163.54M 10-K/A · filed 2025-02-24 |
| 2020-09-30 | $58.09M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $109.53M 10-Q · filed 2021-08-04 |
| 2020-03-31 | $73.81M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $50.31M 10-K · filed 2023-02-27 |
| 2019-09-30 | $51.19M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $32.56M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $21.86M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $26.25M 10-K · filed 2022-02-24 |
| 2018-09-30 | $35.00M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $35.29M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $251.57M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $16.53M 10-K · filed 2021-02-24 |
| 2017-09-30 | $13.63M 10-Q · filed 2018-11-05 |
| 2017-06-30 | $11.22M 10-Q · filed 2018-08-07 |
| 2016-12-31 | $14.53M 10-K · filed 2020-02-25 |
| 2015-12-31 | $12.59M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |